Gene · 369
NIH grants1,471
NIH grants whose papers are about the gene, through NIH's grant-paper links.
481 to 500 of 1,471
Download this page as JSON| Grant | Title | ARAF papers | Newest fiscal year |
|---|---|---|---|
| T32CA211036 | Cancer Targets and Drug Discovery | 1 | 2022 |
| T32GM007055 | Training in the Pharmacological Sciences | 1 | 2022 |
| T32GM008497 | Medical Scientist Training Program | 1 | 2022 |
| T32GM080189 | The Chemistry-Biology Interface Program at Johns Hopkins University | 1 | 2022 |
| U01AG046139 | A Systems Approach to Targeting Innate Immunity in AD | 1 | 2022 |
| U01AG046170 | Integrative Network Biology Approaches to Identify, Characterize and Validate Molecular Subtypes in Alzheimer's Disease | 1 | 2022 |
| U01AG061357 | AMP-AD Brain Proteomic Network Enhancement, Validation, and Translation into CSF Biomarkers | 1 | 2022 |
| U01CA224013 | CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity | 1 | 2022 |
| U01CA233074 | Targeting alternative splicing for TCR discovery in small cell carcinomas | 1 | 2022 |
| U01CA250549 | Development and implementation of multiplex methods to understand the biology and heterogeneity of patient-derived cancer models | 1 | 2022 |
| U01HG007690 | Center for Integrated Approached to Undiagnosed Diseases | 1 | 2022 |
| U54CA225088 | Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule Drugs | 1 | 2022 |
| P01CA154303 | Protein Kinase Therapeutic Targets for Non-Small Cell Lung Carcinoma | 4 | 2021 |
| R01CA105304 | Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics | 4 | 2021 |
| R01CA204314 | Mechanism-based strategies to target oncogenic BRAF signaling | 4 | 2021 |
| R01CA210072 | Quantitative Adductomics Approaches for Assessing the Occurrence and Repair of DNA Adducts | 4 | 2021 |
| U01CA176058 | The Dana-Farber Cancer Institute Cancer Target Discovery and Development Center | 4 | 2021 |
| U54CA209891 | Research Center for Cancer Systems Biology: Cancer Cell Map Initiative | 4 | 2021 |
| R01CA204749 | Understanding Long Tail Driver Mutations in Cancer | 3 | 2021 |
| R01CA211052 | Optimizing biologically-based rational polytherapy in ALK+ lung cancer | 3 | 2021 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/369/grants?page=25